89bio reports Q1 net loss of $51.7M; initiates Phase 3 MASH trial

89bio, Inc.

2024-Q1 EPS reported -$0.54

Net loss $51.7M vs $28.8M YoY; R&D expenses $47.4M (up from $22.3M) on trial ramp-up.
Cash, equivalents & marketable securities $562.3M as of March 31, 2024.
Initiated Phase 3 ENLIGHTEN-Fibrosis trial in MASH F2-F3; ENLIGHTEN-Cirrhosis expected Q2 2024.
EMA granted PRIME status for pegozafermin in MASH; 48-week extension data at EASL June 8.
ENTRUST Phase 3 in severe hypertriglyceridemia enrollment ongoing; topline data expected 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

89bio, Inc. reported the first quarter ended March 31, 2024 results: net income $51.7 million.

Period: the first quarter ended March 31, 2024
Net income: $51.7 million
Result: reported results

Exact text from the filing

89bio reported a net loss of $51.7 million for the three months ended March 31, 2024

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001193125-24-135264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.